Related references
Note: Only part of the references are listed.The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety
Robert A. Copeland
EXPERT OPINION ON DRUG DISCOVERY (2010)
Detection of angiotensin II type 1 receptor ligands by a cell-based assay
Matthias Griessner et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2009)
On the mechanism of the persistent action of salmeterol: what is the current position?
R. A. Coleman
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Molecular mechanisms for the persistent bronchodilatory effect of the beta(2)-adrenoceptor agonist salmeterol
A. Szczuka et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides
Rosalba Mansi et al.
CLINICAL CANCER RESEARCH (2009)
Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling
Bart A. Ploeger et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: Application to (R)-dimethindene occupancy of central histamine H1 receptors
Siobhan Malany et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2009)
Ligands, their receptors and ... plasma membranes
G. Vauquelin et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand
Garth E. Terry et al.
NEUROIMAGE (2009)
Molecular imaging targeting peptide receptors
Margret Schottelius et al.
METHODS (2009)
Antagonist-radioligand binding to D2L-receptors in intact cells
Ann Packeu et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Residence time of receptor-ligand complexes and its effect on biological function
Peter J. Tummino et al.
BIOCHEMISTRY (2008)
Synthesis and evaluation of xanomeline analogs -: Probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor
Brian E. Kane et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET
Zi-Bo Li et al.
CLINICAL CANCER RESEARCH (2008)
Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation
Masahiro Fujita et al.
NEUROIMAGE (2008)
Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor
M. T. Le et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation
Georges Vauquelin et al.
NEUROCHEMISTRY INTERNATIONAL (2007)
Brain and whole-body imaging in nonhuman primates with [11C]MeS-IMPY, a candidate radioligand for β-amyloid plaques
Nicholas Seneca et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor
Christopher E. Heise et al.
JOURNAL OF BIOMOLECULAR SCREENING (2007)
Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes
Ingrid Dijkgraaf et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2007)
Advanced pharmacokinetic models based on organ clearance, circulatory, and Fractal concepts
K. Sandy Pang et al.
AAPS JOURNAL (2007)
Consensus nomenclature for in vivo imaging of reversibly binding radioligands
Robert B. Innis et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2007)
Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor
Mark R. Dowling et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
The extracellular matrix and synapses
Alexander Dityatev et al.
CELL AND TISSUE RESEARCH (2006)
Can binding kinetics translate to a clinically differentiated drug? From theory to practice
David C. Swinney
LETTERS IN DRUG DESIGN & DISCOVERY (2006)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Slow antagonist dissociation and long-lasting in vivo receptor protection
Georges Vauquelin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans
Georges Vauquelin et al.
JOURNAL OF HYPERTENSION (2006)
Diffusion delays and unstirred layer effects at monolayer cultures of chinese hamster ovary cells - Radioligand binding, confocal microscopy, and mathematical simulations
CE Spivak et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2006)
Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: Mechanisms leading to optimal efficacy and safety
David C. Swinney
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2006)
Effect of saponin and filipin on antagonist binding to AT1 receptors in intact cells
I Verheijen et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Effects of the geometry of the immunological synapse on the delivery of effector molecules
D Coombs et al.
BIOPHYSICAL JOURNAL (2004)
Biochemical mechanisms of drug action: what does it take for success?
DC Swinney
NATURE REVIEWS DRUG DISCOVERY (2004)
Contribution of dead-space microdomains to tortuosity of brain extracellular space
S Hrabetová et al.
NEUROCHEMISTRY INTERNATIONAL (2004)
Reaction kinetics in intracellular environments with macromolecular crowding: simulations and rate laws
S Schnell et al.
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2004)
Diversity of mechanism-based pharmacodynamic models
DE Mager et al.
DRUG METABOLISM AND DISPOSITION (2003)
G protein-coupled receptor allosterism and complexing
A Christopoulos et al.
PHARMACOLOGICAL REVIEWS (2002)
Distinct binding properties of the AT1 receptor antagonist [3H]candesartan to intact cells and membrane preparations
FLP Fierens et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel
MA Lovich et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2001)
Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?:: A new hypothesis
S Kapur et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists
G Vauquelin et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors
I Verheijen et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2000)
Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type I receptors
PML Vanderheyden et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
ZH Israili
JOURNAL OF HUMAN HYPERTENSION (2000)
Share Paper
